

Global Macro Strategy

Will another hike lead to higher yields and USD?

Global Macro Strategy

Global

Is this the beginning of the end for the "lower for longer" rates regime?

Over the past few weeks, markets have moved to reflect renewed hope of growth acceleration and inflation recovery. The market has priced in a December Fed hike without much damage to risky assets, and higher oil prices have supported a bounce in inflation expectations. At the same time, the dollar has rallied and curves have steepened globally.

There may be some (limited) room for these moves to extend...

In contrast to the run-up to last year's hike when financial conditions had tightened significantly, financial conditions have eased a lot since February, led by narrower credit spreads and higher equity prices. The Fed is also guiding toward a much less hawkish forward path than they were around the first hike, market pricing is closer to the Fed dots than it was a year-ago, inflation is higher, and with fears around Chinese growth reduced, the global backdrop is better.

... but this is not a regime change

It would take a lot to reverse the "lower for longer" regime. Growth in China and the Euro area would need to pick up alongside US growth, oil prices would need to continue their gradual rise, and most important, central banks (the Fed in particular) would have to remain accommodative. We see it as unlikely that all of these happen in combination. Although financial conditions are easier now than they were for the first hike, the growth pick-up remains modest. Inflation is higher, but inflation expectations remain below target, and the upward pressure from rising foreign yields is likely to dissipate.

What to do? Use opportunities to re-engage in long-standing themes

If, as we expect, the low rates regime persists, we would use backups in US 10-year yields as opportunities to receive, and also to position in flatteners, which we continue to favour. Low rates should continue to support positive returns in equities-- high equity valuations are simply the mirror image of low risk-free yields. In FX, lower US yields against higher yields in the Euro area should support EUR/USD, and we remain bullish. We remain bearish GBP and SEK, even after recent weak performance.

A December Fed hike may open up some tactical opportunities as well

Similar to 2015, short-term volatility may rise into the December FOMC meeting. Data has been sufficiently weak that a hike isn't guaranteed, yet policymakers will want to retain the optionality to hike. This uncertainty could push up volatility, particularly short-term volatility relative to longer-term volatility. VIX and AUD/USD are two examples of volatility curves with some steepness. In FX, if US growth remains soft, AUD and NZD could benefit over time as investors reassess the relative attractiveness of higher-yielding G10 currencies.

Daniel Waldman

Strategist

daniel.waldman@ubs.com

+1-203-719 4281

Jeff Greenberg

Strategist

jeff.greenberg@ubs.com

+1-203-719 1751

Chirag Mirani

Strategist

chirag.mirani@ubs.com

+1-203-719 7514

Themos Fiotakis

Strategist

themos.fiotakis@ubs.com

+44-20-7567 7215

Haojiang Zhao

Associate Strategist

haojiang.zhao@ubs.com

+44-20-7568 5547

Yianos Kontopoulos

Strategist

yianos.kontopoulos@ubs.com

+44-20-7568 8924

Are markets better prepared for a hike this time?

Risk markets have spent much of the year in the macro sweet spot, with growth picking up from very weak levels, yet interest rates remaining low. This has supported risky assets and a continuing search for yield. But with Fed rhetoric, market pricing, and our economists' forecasts all pointing to a December hike, is the sweet spot about to end? Or are markets better prepared for a hike than they were in 2015? This is the key question for markets.

Reflation ahead, or another false start?

Over the past year, we have spent significant time writing about the implications of [low inflation](#) and low trend growth for global assets. Our research has pointed to global yields remaining at [very low levels for longer](#). Lower rates, in turn, enable higher equity valuations, despite slower earnings growth (see [Big Macro 04: Secular stagnation and equities: the new normal](#)). Given the asymmetries in the market's growth expectations for the US versus the rest of the world, these views have, for us, long marked the [peak in the dollar versus DM currencies](#).


An uneventful Fed hike paired with rising inflation expectations that enable back-end yields and the USD to settle at significantly higher levels is a key risk to our views. Recently, markets have moved to reflect renewed hopes of this outcome, as higher oil prices have supported a bounce in inflation expectations, cyclical and bank stocks have outperformed, the USD has rallied, and curves have steepened.

Why there may be some (limited) room for higher rates...

In contrast to the run-up to last year's hike when financial conditions had tightened by a Fed Funds equivalent of 128bp, conditions have eased significantly this year (Figure 1; see [Can one small hike cause a giant tightening?](#)). Since February, rising equities and tighter credit spreads have eased financial conditions by 200bp on our measure, and conditions are easier now than they were when the Fed hiked last (Figure 2).


It is also worth noting that the Fed is guiding to an easier forward path than they were at this time last year. This may imply that there is more room for the Fed to hike than there was last December, as does the fact that US inflation is higher than a year ago. With fears around Chinese growth reduced, the global backdrop is better, and base effects from rising oil prices are pushing up y/y headline inflation.

Figure 1: Financial conditions have eased this year...



Source: UBS, Bloomberg. See ["Can one small hike cause a giant tightening?"](#)

Figure 2: ... mostly because of equities and credit



Source: UBS calculations, Bloomberg.

... but four key reasons why this is not a regime change

Although recent trends can extend, there are limits, and we would view such moves as temporary, rather than as a change in regime.

▪ 1/ It would take a lot to get a continuation of reflationary price action

Growth in China and the Euro area would need to pick up alongside US growth, oil prices would need to continue their gradual rise, and most important, central banks (the Fed in particular), would have to remain accommodative. All of these happening simultaneously is unlikely, in our view.

▪ 2/ Although financial conditions have eased a lot, the growth pick-up has been modest


Despite a significant easing in financial conditions, nominal growth was only 2.5% y/y in Q2 versus 4.0% in Q2 2015. Q3 is seeing some acceleration, but it is been small and mostly noticeable because the starting point was so low. Retail sales have been soft, with core sales annualizing at slightly negative rate during the past three months, the manufacturing ISM is at only 51.5, and payroll growth has downshifted (Figure 3).

This puts the easing in financial conditions in a less positive light. Despite a marked easing, the acceleration in growth has been modest. Although disappointing, this is consistent with what we've seen during the past six years-- easier financial conditions are essentially a prerequisite for better growth, and without them, growth slips.

From a forward-looking perspective, it is important to note that on our measure, the easing in financial conditions stalled in August. If the Fed were to hike in December, it would be difficult for financial conditions to ease between now and year end. The only question is how much further they would tighten.


To be fair, trend growth has slowed (Figure 4), so we need to look at GDP growth numbers differently. The continuing decline in initial jobless claims against a backdrop of 2% GDP growth makes this clear. But if trend growth has slowed, that should work against higher yields, as it suggests a lower equilibrium interest rate. It also means that each hike comes with increased risk relative to past cycles.

Figure 3: The growth pick up has been modest



Source: UBS, Haver Analytics. Scaled relative to post-crisis peak.

Figure 4: Trend growth has slowed



Source: Haver, UBS calculations. *Trend growth calculated using Okun's law with a rolling 8-year window of quarterly data.

▪ 3/ Headline inflation is rising, but base effects are well known

Although higher oil prices are likely to exert upward pressure on headline inflation, there are offsets. If current prices are maintained, it will likely contribute 15-20bp upside to headline and about 5bp to core. But falling food inflation and lower import prices on the back of a stronger USD/CNY will provide partial offsets.

It is fair to worry about markets being complacent regarding the risk of spillovers from headline to core inflation, but it is also true that markets have generally been good at looking through base-effect driven rises in headline CPI. There have been three notable rises in headline CPI since 2010, and in each case, US 10-year yields remained stable or fell (Figure 5).

Furthermore, markets appear to be well-priced for the impact of higher oil prices on inflation. We looked at US one-year CPI swaps and assumed one-year ex-energy inflation (roughly core inflation) persists in order to back out inflation-linked market implied one-year forward crude prices (Figure 6). Notably, the inflation-linked market pricing of crude is almost the same as crude futures market pricing.


Finally, despite the rise in inflation, inflation expectations remain low. Market-based measures have risen significantly from the July lows, but they remain low in absolute terms. Surveys are delivering a similar message, with the University of Michigan's 5-10 year-ahead inflation expectations measure at an all-time low. A December Fed hike, or talk of it, against a backdrop of still-low inflation expectations may contribute to keeping inflation expectations below target.

▪ 4/ Foreign yields helped start the move, but are unlikely to continue it

We have argued that [global yields have had an increased impact on US yields this year](#). In July, we estimated that of the 85bp year-to-date decline in US 10-year yields, foreign yields were responsible for about 48bp, a higher proportion than usual. Since mid-July, US 10-year yields have risen 30bp. Updating our model, we estimate that 7bp has been from higher Bund yields, 5bp has been from JGBs, and 7bp has been from the Gilts (Figure 7, next page).


Going forward, the only place we see room for yields to rise further is the Euro area, while we think it will be difficult for JGBs to sustain a further rise, and in the UK we expect Gilt yields to fall. Even if Bund yields rise another 20bp this year, that would only add another 10bp to US yields in our framework.

Figure 5: Higher headline CPI hasn't pushed up yields



Source: UBS, Bloomberg, BLS.

Figure 6: Markets priced for higher inflation from oil



Source: Bloomberg, UBS calculations.

What to do?

- **There are fresh opportunities to engage in core themes**

In rates, we expect a continuation of the low rate environment. US 10-year yields should fall from current levels, though not quite as much as previously-- we recently [revised our year-end forecast up to 1.60%](#). We would view any rise in US 10-year yields to the 1.80-1.90% range as an opportunity to receive rates, as well as to position in flatteners with a compelling risk-reward.

Equally, we see the steepening in Gilt yields as overdone (despite our bearish GBP views) and also [see favourable risk-reward](#) in receiving the GBP 2y2yF swaps.

The low yield environment is much better priced in the Euro area. We see room for tweaks in the ECB bond buying programme modalities [leading to higher Euro area yields](#), and we forecast Bund yields at 15bp by year end.


In equities, we see room for continuing positive returns. In a low yield environment, equity investors are not complacent. High equity valuations are simply [the mirror image](#) of low risk-free yields. Indeed, our indicator of global risk aversion continues to point to above average levels of cautiousness, albeit much less so than six months ago (Figure 8). Any sell-offs should be viewed as buying opportunities, particularly in dividend stocks, where we remain bullish.

In Europe, the valuation story is a bit different. A 12-month forward P/E of 14.8x doesn't look that cheap, but it is based on trough earnings, and the discount to the US is still at crisis highs. Such a valuation is only justified if there is no earnings growth from here, which is not the expectation of our European equity strategists.

In FX, we remain [bullish EUR/USD](#). The combination of lower US yields and higher German yields should support EUR/USD. The euro remains cheap in our view, and continuing economic re-synchronization between the US and Euro area should gradually push it toward fair value.


We remain bearish GBP and SEK, the two weakest currencies among G10 FX. Given the UK's large current account deficit and need to attract capital, [further adjustment lower in GBP will be necessary](#). We also [remain bearish SEK](#), where persistently low inflation makes long EUR/SEK a good hedge to risk-on positions.

Figure 7: Foreign spillovers to Treasuries



Source: UBS, Bloomberg. Note: Based on vector autoregressive (VAR) model using monthly changes in 10-year yields. See [previous note](#) for details.

Figure 8: Risk aversion fell, but remains above average



Source: UBS calculations, Haver Analytics, Bloomberg.

- **There are tactical opportunities as well**

If growth remains soft, a December Fed hike (or the spectre of one) or rising back-end yields could lead to some weakness in risk assets. [Big Macro 5](#) argues that we should generally avoid trading short-term shifts. Market routs have become more frequent since 2008, sharper and more violent. Yet, have reversed a lot faster than in the past. Sticking with the trend has been the winning trade: back-ups in yields can occur and stir markets – yet a regime shift for stocks and bonds seems unlikely.


Similar to 2015, short-term volatility may rise into the December FOMC meeting. Data has been sufficiently weak that a hike isn't guaranteed, yet policymakers will want to retain the optionality to hike, and lean against market pricing for a December hike falling too far. This uncertainty should push up volatility, particularly short term relative to longer term.

Although Big Macro 5 argues against generally trading short-term shifts, it also notes that a combination of policy, macro, and market variables post-GFC has created dislocations in the term structure of volatility (arguing for flatter volatility curves), making long short-term volatility versus short long-term volatility potentially appealing. Two possible examples: the June 2017 VIX contract is two points above the January 2017, while in AUD/USD, 12-month implied volatility is more than one vol point above 3-month implied volatility.

If weaker data prevents a December hike, or if negative market reaction ensues, AUD and NZD could over time benefit as investors reassess the relative attractiveness of higher-yielding G10 currencies. Any difficulty with a December hike would further embed the lower-for-longer narrative in rates and the search for yield. With Australia and New Zealand continuing to show robust growth (3.3% and 3.6% y/y, respectively), both currencies could benefit. We have moderated our bearish AUD and NZD forecasts in recent months, and are reviewing them again.


Finally, a looming Fed hike may limit near-term upside in risk assets or downside in the dollar. Such impacts are likely to be limited over time, as weaker equities and/or a stronger dollar tighten financial conditions. If either happens to a significant enough degree, the Fed would in all likelihood lean against such moves given the importance of financial conditions to the real economy. Over time, we expect positive equity returns and a weaker dollar. Calendar spreads in equities and FX may be good expressions of these dynamics.

Figure 9: Higher yields have been less benign for equities



Source: Bloomberg, UBS. Rolling 20-day correlation.

Figure 10: Is volatility priced for the next hike's arrival?



Source: Bloomberg, UBS.

Signposts and risks

It is possible that the run-up to the Fed hike is uneventful. Once market pricing for last December's hike reached 60%, the dollar and yields were relatively flat in the final four weeks leading up to the hike. In this regard, it will be important to watch:

- **Inflation expectations**

Inflation expectations are a key barometer for markets and the impact of another hike. Inflation expectations fell sharply around last year's hike, suggesting that markets may have seen Fed policy as overly hawkish. Inflation expectations have risen in recent weeks, but if they are unable to continue rising toward 2.0% and instead fall back lower, market reaction to another Fed hike will likely be negative. Higher rates, without a concurrent rise in inflation expectations, increases real rates and tightens financial conditions, a negative combination for asset markets.

- **USD/CNY**

As it did last year at this time, USD/CNY is rising into the hike. Although the move isn't especially large in nominal or trade-weighted terms, in a world that had gotten used to a persistently stronger CNY, weakness can be disinflationary, both for the US and smaller open economies in Asia. A number of small open economies in Asia, including Singapore and Taiwan, have seen significant currency appreciations versus the CNY this year, and in addition to weighing on competitiveness, it will also push lower already-low inflation, pressuring SGD and TWD.

- **Feedback loops between the dollar, rates, and equities**

We have been writing about [feedback loops](#) between the Fed and markets for a while. These loops provide important limits to policy and price action, as there are limits to the amount of market weakness that a hawkish Fed can cause, as the pass-through to financial conditions ultimately turns the Fed more dovish, creating self-correcting mechanisms. At the same time, risk markets have trouble breaking out, as stronger equity prices impact the Fed's reaction function as well. These dynamics remain in place, and are likely to keep markets difficult to trade.

- **Market pricing of future hikes**

Finally, it is important to watch market pricing. A key difference between the current backdrop and last year's hike is that the market and Fed are currently expecting much shallower paths after this hike than they were last December. At that time, the Fed projected four hikes for 2016 and the market priced about two. Now, the Fed "dots" show expectations of only two hikes in 2017 and the market prices less than one full hike next year. This can be taken positively for risk assets, as it sets an overall more dovish backdrop and implies that markets and the Fed are more aligned this time. But it can also be viewed negatively: if something goes wrong, the Fed and markets have less room to ease expectations for future policy and financial conditions

Valuation Method and Risk Statement

Risks of multi-asset investing include but are not limited to market risk, credit risk, interest rate risk, and foreign exchange risk. Correlations of returns among different asset classes may deviate from historical patterns. Geopolitical events and policy shocks pose risks that can reduce asset returns. Valuations may be adversely affected during times of high market volatility, thin liquidity, and economic dislocation.

Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in related derivatives) that may be the subject of this report. This recommendation was finalized on: 25 October 2016 02:49 AM GMT.

Analyst Certification: Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner, including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set of disclosure statements associated with the companies discussed in this report, including information on valuation and risk, please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.

Options, structured derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Past performance is not necessarily indicative of future results. Various theoretical explanations of the risks associated with these instruments have been published. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The Characteristics and Risks of Standardized Options." You may read the document at <http://www.optionsclearing.com/about/publications/character-risks.jsp> or ask your salesperson for a copy.

Global Disclaimer

This document has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

Global Research is provided to our clients through UBS Neo and, in certain instances, UBS.com (each a "System"). It may also be made available through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client relationship with UBS and legal and regulatory constraints.

All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.

When you receive Global Research through a System, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the terms of use governing the applicable System.

When you receive Global Research via a third party vendor, e-mail or other electronic means, your use shall be subject to this Global Research Disclaimer and to UBS's Terms of Use/Disclaimer (<http://www.ubs.com/global/en/legalinfo2/disclaimer.html>). By accessing and/or using Global Research in this manner, you are indicating that you have read and agree to be bound by our Terms of Use/Disclaimer. In addition, you consent to UBS processing your personal data and using cookies in accordance with our Privacy Statement (<http://www.ubs.com/global/en/legalinfo2/privacy.html>) and cookie notice (<http://www.ubs.com/global/en/homepage/cookies/cookie-management.html>).

If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative work, transfer to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.

This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject UBS to any registration or licensing requirement within such jurisdiction. It is published solely for information purposes; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial instruments or to participate in any particular trading strategy. No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in this document ("the Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party.

Nothing in this document constitutes a representation that any investment strategy or recommendation is suitable or appropriate to an investor's individual circumstances or otherwise constitutes a personal recommendation. Investments involve risks, and investors should exercise prudence and their own judgement in making their investment decisions. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries, clients should contact their local sales representative.

The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising out of the use of all or any of the Information.

Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.

This document and the Information are produced by UBS as part of its research function and are provided to you solely for general background information. UBS has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient. In no circumstances may this document or any of the Information be used for any of the following purposes:

- (i) valuation or accounting purposes;
- (ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
- (iii) to measure the performance of any financial instrument.

By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for any of the above purposes or otherwise rely upon this document or any of the Information.

UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.

Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management, which will also have sole discretion on the timing and frequency of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by the Market Abuse Regulation, can be found on NEO. Different assumptions could result in materially different results.

The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering, applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.

For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is distributed by UBS Limited to persons who are eligible counterparties or professional clients. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. **France:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France S.A. UBS Securities France S.A. is regulated by the ACPR (Autorité de Contrôle Prudentiel et de Résolution) and the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France S.A. has contributed to this document, the document is also deemed to have been prepared by UBS Securities France S.A. **Germany:** Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). **Spain:** Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Comisión Nacional del Mercado de Valores (CNMV). **Turkey:**

Distributed by UBS Limited. No information in this document is provided for the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer made or to be made to residents of the Republic of Turkey. UBS AG is not licensed by the Turkish Capital Market Board under the provisions of the Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article 15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey.

Poland: Distributed by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Limited (spółka z ograniczoną odpowiedzialnością) Oddział w Polsce.

Russia: Prepared and distributed by UBS Bank (OOO).

Switzerland: Distributed by UBS AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA).

Italy: Prepared by UBS Limited and distributed by UBS Limited and UBS Limited, Italy Branch. Where an analyst of UBS Limited, Italy Branch has contributed to this document, the document is also deemed to have been prepared by UBS Limited, Italy Branch.

South Africa: Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an authorised user of the JSE and an authorised Financial Services Provider (FSP 7328).

Israel: This material is distributed by UBS Limited. UBS Limited is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. UBS Securities Israel Ltd is a licensed Investment Marketer that is supervised by the Israel Securities Authority (ISA). UBS Limited and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law. UBS Limited is not covered by insurance as required from a licensee under the Israeli Advisory Law. UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS Limited and its affiliates may prefer various Financial Assets to which they have or may have Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible Clients within the meaning of the Israeli Advisory Law, and this material must not be relied on or acted upon by any other persons.

Saudi Arabia: This document has been issued by UBS AG (and/or any of its subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37.

Dubai: The information distributed by UBS AG Dubai Branch is intended for Professional Clients only and is not for further distribution within the United Arab Emirates.

United States: Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not registered as a US broker-dealer (a "non-US affiliate") to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for the content of a document prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US person in the securities mentioned in this document must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the "Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal Advisor Rule.

Canada: Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration.

Mexico: This report has been distributed and prepared by UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, an entity that is part of UBS Grupo Financiero, S.A. de C.V. and is an affiliate of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research reports only reflect the views of the analysts responsible for the reports. Analysts do not receive any compensation from persons or entities different from UBS Casa de Bolsa, S.A. de C.V., UBS Grupo Financiero, or different from entities belonging to the same financial group or business group of such. For Spanish translations of applicable disclosures, please see www.ubs.com/disclosures.

Brazil: Except as otherwise specified herein, this material is prepared by UBS Brasil CCTVM S.A. to persons who are eligible investors residing in Brazil, which are considered to be: (i) financial institutions, (ii) insurance firms and investment capital companies, (iii) supplementary pension entities, (iv) entities that hold financial investments higher than R\$300,000.00 and that confirm the status of qualified investors in written, (v) investment funds, (vi) securities portfolio managers and securities consultants duly authorized by Comissão de Valores Mobiliários (CVM), regarding their own investments, and (vii) social security systems created by the Federal Government, States, and Municipalities.

Hong Kong: Distributed by UBS Securities Asia Limited and/or UBS AG, Hong Kong Branch.

Singapore: Distributed by UBS Securities Pte. Ltd. [MCI (P) 007/09/2016 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289).

Japan: Distributed by UBS Securities Japan Co., Ltd. to professional investors (except as otherwise permitted). Where this document has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher and distributor of the document. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other banking businesses when relevant.

Australia: Clients of UBS AG: Distributed by UBS AG (Holder of Australian Financial Services License No. 231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (Holder of Australian Financial Services License No. 231098). This document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the information in this document has been prepared without taking into account any investor's objectives, financial situation or needs, and investors should, before acting on the information, consider the appropriateness of the information, having regard to their objectives, financial situation and needs. If the information contained in this document relates to the acquisition, or potential acquisition of a particular financial product by a 'Retail' client as defined by section 761G of the Corporations Act 2001 where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before making any decision about whether to acquire the product. The UBS Securities Australia Limited Financial Services Guide is available at: www.ubs.com/ecs-research-fsg.

New Zealand: Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New Zealand. The information and recommendations in this publication are provided for general information purposes only. To the extent that any such information or recommendations constitute financial advice, they do not take into account any person's particular financial situation or goals. We recommend that recipients seek advice specific to their circumstances from their financial advisor.

Korea: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This document may have been edited or contributed to from time to time by affiliates of UBS Securities Pte. Ltd., Seoul Branch.

Malaysia: This material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is intended for professional/institutional clients only and not for distribution to any retail clients.

India: Distributed by UBS Securities India Private Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: +912261556000. It provides brokerage services bearing SEBI Registration Numbers: NSE (Capital Market Segment): INB230951431, NSE (F&O Segment) INF230951431, NSE (Currency Derivatives Segment) INE230951431, BSE (Capital Market Segment) INB010951437; merchant banking services bearing SEBI Registration Number: INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at: http://www.ubs.com/global/en/about_ubs/investor_relations/annualreporting.html

The disclosures contained in research documents produced by UBS Limited shall be governed by and construed in accordance with English law.

UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements that are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2016. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.

